Vista Medical Technologies, Inc.
This article was originally published in The Gray Sheet
Files with SEC for a 7 mil.-share secondary offering. The Carlsbad, California maker of 3-D visualization equipment for minimally invasive surgery had announced in July a headcount and expense reduction effort and plans to seek additional capital, citing slower than anticipated sales growth for its advanced visualization and information integration platform (1"The Gray Sheet" July 19, In Brief)
You may also be interested in...
Slower than anticipated sales growth for the firm's advanced visualization and information integration platform used in minimally invasive surgical procedures is cited by the firm in announcing July 14 a headcount reduction and cuts in operating expenses. The firm, which went public via an initial stock offering in 1997 ("The Gray Sheet" March 17, 1997, p. 11), is seeking to raise capital "or to effect a sale or merger of the company"
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.